Retatrutide Research Overview

Retatrutide (also studied under the developmental code LY3437943) is a synthetic peptide that simultaneously targets the GIP, GLP-1, and glucagon receptors -- often described in the literature as a "triple agonist" or "GGG tri-agonist."

Retatrutide is an investigational compound studied in real human clinical trials, but has no FDA-approved drug product under any name (see below) -- trial and regulatory status can change, and should be independently verified rather than assumed current. This research-labeled product is not derived from, and has no connection to, any pharmaceutical trial material, and is not intended for human administration.

Unlike most compounds in this catalog, retatrutide is not confined to preclinical research -- it is the subject of an active human clinical trial program by its originating pharmaceutical company:

• Investigational clinical program — retatrutide has been evaluated in randomized human clinical trials conducted by its originating pharmaceutical company as part of an ongoing investigational drug development program.
• Multi-receptor mechanism research — as a triple agonist, retatrutide has been studied for how simultaneously engaging three distinct incretin/glucagon-family receptors compares mechanistically to single- or dual-receptor agonists in the same drug class.
• Metabolic-pathway research — preclinical research has examined retatrutide's association with lipid-metabolism signaling pathways alongside its primary receptor targets.

These are summaries of published research topics, not claims about what this product does, and animal-model findings do not establish an effect in humans.